The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -0.35 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -3.25 — no flag raisedOK
- Earnings quality 70/100 — worth a closer lookWatch
Leadership changes
From Metagenomi Therapeutics, Inc.'s own filings, the day they're filed.
- Brian C. Thomas · directors · departureeff. 2026-06-09
- Eric Bjerkholt · director · appointmenteff. 2025-01-27
Latest filings
- 8-K · Company announcement2026-08-10
- 10-Q · Quarterly report2026-08-10
- 8-K · Company announcement2026-06-10
- 10-Q · Quarterly report2026-05-11
- 8-K · Company announcement2026-05-11
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Metagenomi Therapeutics, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Metagenomi Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.